Table 6.
ATN classification in regard to the biomarker profile and cognitive stage among participants with cerebrospinal fluid (CSF) AD biomarker results.
| ATN Profile | Biomarker Category | Syndromal Cognitive Stage | |||
|---|---|---|---|---|---|
| CN (n = 29) | SCD (n = 58) |
MCI (n = 29) |
ADD (n = 23) |
||
| A−/T−/N− | Normal AD biomarkers | 20 (69.0%) | 13 (22.4%) | 2 (6.9%) | 0 |
| A+/T−/N− | Alzheimer’s pathologic change | 1 (3.4%) | 1 (1.7%) | 3 (10.3%) | 0 |
| A+/T+/N− | Alzheimer’s disease | 0 | 3 (5.2%) | 2 (6.9%) | 1 (4.4%) |
| A+/T+/N+ | Alzheimer’s disease | 0 | 6 (10.3%) | 7 (24.1%) | 17 (73.9%) |
| A+/T−/N+ | Alzheimer’s and SNAP | 2 (6.9%) | 4 (6.9%) | 4 (13.8%) | 3 (13.0%) |
| A−/T+/N− | Non-AD pathologic change | 2 (6.9%) | 0 | 2 (6.9%) | 0 |
| A−/T+/N+ | Non-AD pathologic change | 0 | 3 (5.2%) | 3 (10.3%) | 0 |
| A−/T−/N+ | Non-AD pathologic change | 4 (13.8%) | 28 (48.3%) | 6 (20.7%) | 2 (8.7%) |
Data are shown as number (%). CN, cognitively normal; SCD, subjective cognitive decline; MCI, mild cognitive impairment; ADD, Alzheimer’s disease dementia; ATN, amyloid, tau, and neurodegeneration or neuronal injury; A−, absence of amyloid pathology determined by normal amyloid PET finding or CSF Aβ42 level above cut point; A+, presence of amyloid pathology determined by abnormal amyloid PET finding or CSF Aβ42 level below cut point; T−, normal CSF p-tau level below cut point; T+, abnormal CSF p-tau above cut point; N−, absence of neurodegeneration or neuronal injury determined by cortical thickness or hippocampal volume; N+, presence of neurodegeneration or neuronal injury determined by cortical thickness or hippocampal volume; SNAP, suspected non Alzheimer’s pathologic change.